Helus

• Helus Pharma has appointed Michael Halstead, the former President of Intra-Cellular Therapies, as its new Chief Executive Officer. • The company successfully completed patient enrollment for its Phase 3 APPROACH study evaluating the drug candidate HLP003. • To support late-stage development and future commercialization, Helus Pharma has secured $50 million in new funding.

• Helus Pharma reported its financial results for the first quarter of fiscal 2027, ending June 30, 2026, alongside key business updates. • The company appointed former Intra-Cellular Therapies President Michael Halstead as CEO to oversee late-stage development and future commercialization efforts. • Enrollment has been completed for the Phase 3 APPROACH pivotal study evaluating HLP003 for the treatment of Major Depressive Disorder (MDD).

• Helus Pharma has released its financial results for the first quarter of fiscal 2027 and shared recent business updates. • The company appointed Michael Halstead, the former President of Intra-Cellular Therapies, as its new Chief Executive Officer. • Halstead is tasked with guiding the company through the critical phases of late-stage development and eventual commercialization.